Microbot Medical (MBOT) Fundamental Analysis: Revenue, Earnings & Valuation

1.00 / 10

Underperform

The fundamental assessment rates the company as Underperform with a 1/10 score. Positive factors include Profit‑MV and Cash‑UP, but Cash‑MV, ROA and other profitability ratios are negative, indicating poor financial health and limited upside potential.

Analysis Checks(2/10)

ROA (%)

Value-22.05

Score0/3

Weight19.61%

1M Return-6.12%

Annualized return on equity (%)

Value-31.57

Score1/3

Weight8.88%

1M Return-2.02%

Profit-MV

Value0.41

Score2/3

Weight-17.92%

1M Return3.26%

Cash-UP

Value-0.01

Score2/3

Weight16.35%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-29.40

Score0/3

Weight19.61%

1M Return-6.12%

ROE (diluted) (%)

Value-12.37

Score1/3

Weight6.23%

1M Return-1.41%

Asset-MV

Value-0.48

Score0/3

Weight14.36%

1M Return-3.34%

ROE (%)

Value-23.68

Score1/3

Weight8.88%

1M Return-2.02%

Cash-MV

Value-0.09

Score1/3

Weight14.09%

1M Return-3.56%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight9.92%

1M Return-2.37%

Is MBOT fundamentally strong?

MBOT scores 1.00/10 on fundamentals and holds a Premium valuation at present. Backed by its -32.42% ROE, 0.00% net margin, -12.21 P/E ratio, 2.07 P/B ratio, and 60.27% earnings growth, these metrics solidify its Underperform investment rating.